2023-508646-18-00招募中2 期
A 4-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamic, and exploratory efficacy of venglustat in combination with Cerezyme in adult patients with Gaucher disease Type 3 with venglustat monotherapy extension
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Number of participants with Treatment Emergent Adverse Events (TEAEs)
研究概览
简要总结
Part 1: Biomarker evaluation/screening phase • Evaluate cerebrospinal fluid (CSF) biomarkers in adult Gaucher disease Type 3 (GD3) participants that distinguish GD3 from adult Gaucher disease Type 1 (GD1) participants • Screen adult GD3 participants who qualify for treatment with venglustat in Parts 2, Part 3, and Part 4 Parts 2 and 3: Combination treatment phases • Evaluate short-term (Part 2) and long-term (Part 3) safety and tolerability of venglustat in combination with Cerezyme in adult GD3 participants • Evaluate the change in CSF central nervous system (CNS) biomarkers (glucosylceramide [GL-1] and lyso-glucosylceramide [lyso-GL-1]) from adult GD3 participants receiving venglustat in combination with Cerezyme (Part 2 only) Part 4: Extended treatment phase with monotherapy • Evaluate safety and tolerability of venglustat monotherapy in adult GD3 participants who have remained systemically stable on venglustat in combination with Cerezyme
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •GD1 participant is ≥18 and ≤40 years of age.
- •Participant is willing to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for 72 hours prior to administration of the first dose of venglustat and for the duration of the treatment period.
- •Oculomotor apraxia characterized by a horizontal saccade abnormality.
- •Female participants of childbearing potential and male participants must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use 2 acceptable effective methods of contraception for the duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of venglustat.
- •GD3 participant is ≥18 years of age.
- •Participant must provide written informed consent prior to any study-related procedures being performed.
- •Participant has a clinical diagnosis of Gaucher disease Type 1 (GD1) or Gaucher disease Type 3 (GD3) and documented deficiency of acid beta-glucosidase activity confirming this diagnosis.
- •Participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months and is within the therapeutic goals defined below, and is deemed clinically stable for at least 1 year by the Investigator.
- •Participant has reached Gaucher disease therapeutic goals defined as all of the following to be eligible for this study: -Hemoglobin level of ≥11.0 g/dL for females and ≥12.0 g/dL for males. -Platelet count ≥100,000/mm
- •Spleen volume <10 multiples of normal (MN), or total splenectomy (provided the splenectomy occurred >3 years prior to randomization). -Liver volume <1.5 MN. -No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening.
- •Participant has maintained GD therapeutic goals defined as all of the following to be eligible for entering Part 4 of this study: -Hemoglobin level of ≥11.0 g/dL for females and ≥12.0 g/dL for males -Platelet count ≥100 000/mm3 -Spleen volume <10 multiples of normal (MN), or total splenectomy -Liver volume <1.5 MN -No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to entering Part 4
- •Participant, if female and of childbearing potential, must have a negative pregnancy test [urine beta-human chorionic gonadotropin (β-hCG)] at baseline.
- •If participant has a history of seizures, except for myoclonic seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of cytochrome P450 (CYP) 3A.
排除标准
- •Participant has myoclonic seizures.
- •Participant has had a major organ transplant (e.g., bone marrow or liver).
- •Substrate reduction therapy or chaperone therapy for GD within 6 months prior to enrollment.
- •Participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (e.g., contraindications for magnetic resonance imaging).
- •Participant has had a partial or total splenectomy within 3 years prior to randomization.
- •Participant is blood transfusion-dependent.
- •Prior esophageal varices or liver infarction or current liver enzymes (alanine aminotransferase [ALT]/ aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal, unless the participant has a diagnosis of Gilbert Syndrome.
- •Participant has any clinically significant disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation.
- •Participant has renal insufficiency, as defined by an estimated glomerular filtration rate <30 mL/min/1.73m2 at the screening visit.
- •Participant has received an investigational product within 30 days prior to enrollment.
- •Participant has a history of cancer, with the exception of basal cell carcinoma.
- •Participant is pregnant or lactating.
- •Participant has, according to World Health Organization (WHO) Grading, a cortical cataract > one-quarter of the lens circumference (Grade cortical cataract-2) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2). Participants with nuclear cataracts will not be excluded.
- •Participant requires use of invasive ventilatory support.
- •Participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily.
- •Participant is unable to receive treatment with Cerezyme due to a known hypersensitivity or is unwilling to receive Cerezyme treatment to ensure maintenance of Gaucher treatment goals.
- •Participant is currently receiving potentially cataractogenic medications (corticosteroids, psoralens used in dermatology with ultraviolet light therapy [PUVA], typical antipsychotics, and glaucoma medications) or any medication that may worsen the vision of a participant with cataract (eg, alphaadrenergic glaucoma medications).
- •Participant has received strong or moderate inducers or inhibitors of CYP3A within 15 days or 5 half-lives from screening, whichever is longer, prior to enrolment in Part
- •This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration in Parts 2 and
- •Participant is scheduled for in-patient hospitalization including elective surgery, during the study.
结局指标
主要结局
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in cerebrospinal fluid (CSF)
Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in cerebrospinal fluid (CSF)
次要结局
- Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in plasma
- Assessment of plasma pharmacokinetic parameter: Cmax (Part 2)
- Assessment of plasma pharmacokinetic parameter: Tmax (Part 2)
- Assessment of plasma pharmacokinetic parameter: AUC 0-24h (Part2)
- Assessment of plasma pharmacokinetic parameter: Ctrough
- Assessment of CSF pharmacokinetic parameter: Cmax
- Assessment of platelet level (Part 4)
- Assessment of spleen volume
- Assessment of spleen volume (Part4)
- Assessment of liver volume
- Assessment of liver volume (Part 4)
- Assessment of Ataxia
- Assessment of hemoglobin level
- Assessment of hemoglobin level (Part 4)
- Assessment of platelet level
- Assessment of Ataxia (Part 4)
研究者
Clinical Sciences and Operations
Scientific
Genzyme Corp.
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72
进行中（未招募）
2 期
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER3-EXPRESSING ADVANCED BREAST CANCER AND NON–SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM HER3-EXPRESSING ADVANCED SOLID TUMORS (The TUXEDO-3 Study)2023-503251-10-00Medica Scientia Innovation Research S.L.60
招募中
4 期
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye DiseaseThyroid Eye DiseaseNCT07265258Innovent Biologics (Suzhou) Co. Ltd.92
招募中
不适用
SUCCESS Score Validation in Fuchs DystrophyNCT07265388Instituto Ramón y Cajal de Investigación Sanitaria250
招募中
2 期
CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substudy 1: A Study to Collect Patient-Level Data in Patients with Multiple Myeloma CO43923 Substudy 2 Cevos + Len Treatment: A Study Evaluating the Safety and Efficacy of Cevostamab in Combination with Lenalidomide in Patients with Cytogenetic High-Risk Features Receiving Maintenance Treatment After First Response from Multiple Myeloma Post-Stem Cell Transplant CO43923 Substudy 4 Cevostamab+ Iberdomide Treatment: A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Combination with Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma2023-504484-16-00F. Hoffmann-La Roche AG32